January 4, 2018 / 5:41 PM / 9 months ago

BRIEF-Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy

Jan 4 (Reuters) - Celsion Corp:

* CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER

* CELSION CORP - EXPECTS TO INITIATE ENROLLMENT OF PHASE I PORTION OF OVATION II STUDY IN FIRST HALF OF 2018

* CELSION CORP - COMPANY EXPECTS TO HAVE 25% OF OVATION II STUDY ENROLLED BY END OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below